Beta-hpv 5 and 8 E6 promote p300 degradation by blocking AKT/p300 association

PLoS Pathogens

Volumn 7, Issue 8, 2011, Pages

  Howie, Heather L ^a   Koop, Jennifer I ^a   Weese, Joleen ^a   Robinson, Kristin ^a   Wipf, Greg ^a   Kim, Leslie ^b   Galloway, Denise A ^a  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 E6 PROTEIN; INVOLUCRIN; PROTEIN E6; PROTEIN KINASE B; PROTEIN P300; UNCLASSIFIED DRUG; E1A ASSOCIATED P300 PROTEIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 5; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 8; EP300 PROTEIN, HUMAN; ONCOPROTEIN; PROTEASOME;

ALPHA HUMAN PAPILLOMAVIRUS; ARTICLE; BETA HUMAN PAPILLOMAVIRUS TYPE 5; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; WART VIRUS; GENETIC MARKER; GENETIC TRANSCRIPTION; GENETICS; KERATINOCYTE; METABOLISM; PAPILLOMA VIRUS; VIROLOGY;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

CELL DIFFERENTIATION; E1A-ASSOCIATED P300 PROTEIN; GENETIC MARKERS; HUMANS; KERATINOCYTES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 80052318912     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002211     Document Type: Article

References (80)

1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, et al. (2010) Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401: 70-79.
2. zur Hausen H, (1999) Papillomaviruses in human cancers. Proc Assoc Am Physicians 111: 581-587.
3. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, et al. (2005) Carcinogenicity of human papillomaviruses. Lancet Oncol 6: 204.
4. Bouwes Bavinck JN, Feltkamp M, Struijk L, ter Schegget J, (2001) Human papillomavirus infection and skin cancer risk in organ transplant recipients. J Investig Dermatol Symp Proc 6: 207-211.
5. Orth G, Jablonska S, Jarzabek-Chorzelska M, Obalek S, Rzesa G, et al. (1979) Characteristics of the lesions and risk of malignant conversion associated with the type of human papillomavirus involved in epidermodysplasia verruciformis. Cancer Res 39: 1074-1082.
6. Lutzner MA, Blanchet-Bardon C, Orth G, (1984) Clinical observations, virologic studies, and treatment trials in patients with epidermodysplasia verruciformis, a disease induced by specific human papillomaviruses. J Invest Dermatol 83: 18s-25s.
7. Pfister H, (1992) Human papillomaviruses and skin cancer. Semin Cancer Biol 3: 263-271.
8. Howie HL, Katzenellenbogen RA, Galloway DA, (2009) Papillomavirus E6 proteins. Virology 384: 324-334.
9. McLaughlin-Drubin ME, Munger K, (2009) The human papillomavirus E7 oncoprotein. Virology 384: 335-344.
10. Huibregtse JM, Scheffner M, Howley PM, (1991) A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. Embo J 10: 4129-4135.
11. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM, (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495-505.
12. Chen JJ, Hong Y, Rustamzadeh E, Baleja JD, Androphy EJ, (1998) Identification of an alpha helical motif sufficient for association with papillomavirus E6. J Biol Chem 273: 13537-13544.
13. Kuballa P, Matentzoglu K, Scheffner M, (2007) The role of the ubiquitin ligase E6-AP in human papillomavirus E6-mediated degradation of PDZ domain-containing proteins. J Biol Chem 282: 65-71.
14. Thomas M, Banks L, (1999) Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J Gen Virol 80 (Pt 6): 1513-1517.
15. Thomas M, Banks L, (1998) Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 17: 2943-2954.
16. Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, et al. (1998) Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396: 84-88.
17. Klingelhutz AJ, Foster SA, McDougall JK, (1996) Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 380: 79-82.
18. Veldman T, Liu X, Yuan H, Schlegel R, (2003) Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc Natl Acad Sci U S A 100: 8211-8216.
19. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM, (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
20. Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T, et al. (1997) Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 94: 11612-11616.
21. Lee SS, Weiss RS, Javier RT, (1997) Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 94: 6670-6675.
22. Nakagawa S, Huibregtse JM, (2000) Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol Cell Biol 20: 8244-8253.
23. Glaunsinger BA, Lee SS, Thomas M, Banks L, Javier R, (2000) Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene 19: 5270-5280.
24. Thomas M, Glaunsinger B, Pim D, Javier R, Banks L, (2001) HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene 20: 5431-5439.
25. Lee SS, Glaunsinger B, Mantovani F, Banks L, Javier RT, (2000) Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. J Virol 74: 9680-9693.
26. Jing M, Bohl J, Brimer N, Kinter M, Vande Pol SB, (2007) Degradation of tyrosine phosphatase PTPN3 (PTPH1) by association with oncogenic human papillomavirus E6 proteins. J Virol 81: 2231-2239.
27. Spanos WC, Hoover A, Harris GF, Wu S, Strand GL, et al. (2008) The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth. J Virol 82: 2493-2500.
28. Thomas M, Dasgupta J, Zhang Y, Chen X, Banks L, (2008) Analysis of specificity determinants in the interactions of different HPV E6 proteins with their PDZ domain-containing substrates. Virology 376: 371-378.
29. Underbrink MP, Howie HL, Bedard KM, Koop JI, Galloway DA, (2008) E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J Virol 82: 10408-10417.
30. Bedard KM, Underbrink MP, Howie HL, Galloway DA, (2008) The E6 oncoproteins from human betapapillomaviruses differentially activate telomerase through an E6AP-dependent mechanism and prolong the lifespan of primary keratinocytes. J Virol 82: 3894-3902.
31. Accardi R, Dong W, Smet A, Cui R, Hautefeuille A, et al. (2006) Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep 7: 334-340.
32. Dong W, Arpin C, Accardi R, Gissmann L, Sylla BS, et al. (2008) Loss of p53 or p73 in human papillomavirus type 38 E6 and E7 transgenic mice partially restores the UV-activated cell cycle checkpoints. Oncogene 27: 2923-2928.
33. Muller-Schiffmann A, Beckmann J, Steger G, (2006) The E6 protein of the cutaneous human papillomavirus type 8 can stimulate the viral early and late promoters by distinct mechanisms. J Virol 80: 8718-8728.
34. Zimmermann H, Degenkolbe R, Bernard HU, O'Connor MJ, (1999) The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J Virol 73: 6209-6219.
35. Zimmermann H, Koh CH, Degenkolbe R, O'Connor MJ, Muller A, et al. (2000) Interaction with CBP/p300 enables the bovine papillomavirus type 1 E6 oncoprotein to downregulate CBP/p300-mediated transactivation by p53. J Gen Virol 81: 2617-2623.
36. Patel D, Huang SM, Baglia LA, McCance DJ, (1999) The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. Embo J 18: 5061-5072.
37. Muench P, Probst S, Schuetz J, Leiprecht N, Busch M, et al. (2010) Cutaneous Papillomavirus E6 Proteins Must Interact with p300 and Block p53-Mediated Apoptosis for Cellular Immortalization and Tumorigenesis. Cancer Res 70: 6913-6924.
38. Thomas MC, Chiang CM, (2005) E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell 17: 251-264.
39. Giles RH, Peters DJ, Breuning MH, (1998) Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 14: 178-183.
40. Goodman RH, Smolik S, (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev 14: 1553-1577.
41. Kao WH, Beaudenon SL, Talis AL, Huibregtse JM, Howley PM, (2000) Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase. J Virol 74: 6408-6417.
42. Chen J, Halappanavar SS, St-Germain JR, Tsang BK, Li Q, (2004) Role of Akt/protein kinase B in the activity of transcriptional coactivator p300. Cell Mol Life Sci 61: 1675-1683.
43. Huang WC, Chen CC, (2005) Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol Cell Biol 25: 6592-6602.
44. Guo S, Cichy SB, He X, Yang Q, Ragland M, et al. (2001) Insulin suppresses transactivation by CAAT/enhancer-binding proteins beta (C/EBPbeta). Signaling to p300/CREB-binding protein by protein kinase B disrupts interaction with the major activation domain of C/EBPbeta. J Biol Chem 276: 8516-8523.
45. Gupta S, Stuffrein S, Plattner R, Tencati M, Gray C, et al. (2001) Role of phosphoinositide 3-kinase in the aggressive tumor growth of HT1080 human fibrosarcoma cells. Mol Cell Biol 21: 5846-5856.
46. Wen HC, Huang WC, Ali A, Woodgett JR, Lin WW, (2003) Negative regulation of phosphatidylinositol 3-kinase and Akt signalling pathway by PKC. Cell Signal 15: 37-45.
47. Vlahos CJ, Matter WF, Hui KY, Brown RF, (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269: 5241-5248.
48. Wong PP, Pickard A, McCance DJ, (2010) p300 alters keratinocyte cell growth and differentiation through regulation of p21(Waf1/CIP1). PLoS One 5: e8369.
49. Crish JF, Eckert RL, (2008) Synergistic activation of human involucrin gene expression by Fra-1 and p300-evidence for the presence of a multiprotein complex. J Invest Dermatol 128: 530-541.
50. Sinitsyna NN, Reznikova TV, Qin Q, Song H, Phillips MA, et al. (2010) Arsenite suppression of involucrin transcription through AP1 promoter sites in cultured human keratinocytes. Toxicol Appl Pharmacol 243: 275-282.
51. Iyer NG, Ozdag H, Caldas C, (2004) p300/CBP and cancer. Oncogene 23: 4225-4231.
52. Kalkhoven E, (2004) CBP and p300: HATs for different occasions. Biochem Pharmacol 68: 1145-1155.
53. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, et al. (2000) Mutations truncating the EP300 acetylase in human cancers. Nat Genet 24: 300-303.
54. Bryan EJ, Jokubaitis VJ, Chamberlain NL, Baxter SW, Dawson E, et al. (2002) Mutation analysis of EP300 in colon, breast and ovarian carcinomas. Int J Cancer 102: 137-141.
55. Garbati MR, Alco G, Gilmore TD, (2009) Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8. Cancer Lett 291: 237-245.
56. Muraoka M, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Shitara N, et al. (1996) p300 gene alterations in colorectal and gastric carcinomas. Oncogene 12: 1565-1569.
57. Suganuma T, Kawabata M, Ohshima T, Ikeda MA, (2002) Growth suppression of human carcinoma cells by reintroduction of the p300 coactivator. Proc Natl Acad Sci U S A 99: 13073-13078.
58. Rebel VI, Kung AL, Tanner EA, Yang H, Bronson RT, et al. (2002) Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci U S A 99: 14789-14794.
59. Arany Z, Newsome D, Oldread E, Livingston DM, Eckner R, (1995) A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. Nature 374: 81-84.
60. Chakravarti D, Ogryzko V, Kao HY, Nash A, Chen H, et al. (1999) A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell 96: 393-403.
61. Colgin MA, Nyborg JK, (1998) The human T-cell leukemia virus type 1 oncoprotein Tax inhibits the transcriptional activity of c-Myb through competition for the CREB binding protein. J Virol 72: 9396-9399.
62. Hamamori Y, Sartorelli V, Ogryzko V, Puri PL, Wu HY, et al. (1999) Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. Cell 96: 405-413.
63. Kwok RP, Laurance ME, Lundblad JR, Goldman PS, Shih H, et al. (1996) Control of cAMP-regulated enhancers by the viral transactivator Tax through CREB and the co-activator CBP. Nature 380: 642-646.
64. Granja AG, Nogal ML, Hurtado C, Del Aguila C, Carrascosa AL, et al. (2006) The viral protein A238L inhibits TNF-alpha expression through a CBP/p300 transcriptional coactivators pathway. J Immunol 176: 451-462.
65. Granja AG, Sanchez EG, Sabina P, Fresno M, Revilla Y, (2009) African swine fever virus blocks the host cell antiviral inflammatory response through a direct inhibition of PKC-theta-mediated p300 transactivation. J Virol 83: 969-980.
66. Kasper LH, Lerach S, Wang J, Wu S, Jeevan T, et al. (2010) CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation. Embo J 29: 3660-3672.
67. Krubasik D, Iyer NG, English WR, Ahmed AA, Vias M, et al. (2006) Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition. Br J Cancer 94: 1326-1332.
68. Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, et al. (1999) Function for p300 and not CBP in the apoptotic response to DNA damage. Oncogene 18: 5714-5717.
69. James MA, Lee JH, Klingelhutz AJ, (2006) HPV16-E6 associated hTERT promoter acetylation is E6AP dependent, increased in later passage cells and enhanced by loss of p300. Int J Cancer 119: 1878-1885.
70. Santos M, Paramio JM, Bravo A, Ramirez A, Jorcano JL, (2002) The expression of keratin k10 in the basal layer of the epidermis inhibits cell proliferation and prevents skin tumorigenesis. J Biol Chem 277: 19122-19130.
71. Paramio JM, Casanova ML, Segrelles C, Mittnacht S, Lane EB, et al. (1999) Modulation of cell proliferation by cytokeratins K10 and K16. Mol Cell Biol 19: 3086-3094.
72. Paramio JM, Segrelles C, Ruiz S, Jorcano JL, (2001) Inhibition of protein kinase B (PKB) and PKCzeta mediates keratin K10-induced cell cycle arrest. Mol Cell Biol 21: 7449-7459.
73. Akgul B, Ghali L, Davies D, Pfister H, Leigh IM, et al. (2007) HPV8 early genes modulate differentiation and cell cycle of primary human adult keratinocytes. Exp Dermatol 16: 590-599.
74. Barcelos AC, Sotto MN, (2009) Comparative analysis of the expression of cytokeratins (1, 10, 14, 16, 4), involucrin, filaggrin and e-cadherin in plane warts and epidermodysplasia verruciformis plane wart-type lesions. J Cutan Pathol 36: 647-654.
75. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, et al. (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12: 2831-2841.
76. Dornan D, Shimizu H, Perkins ND, Hupp TR, (2003) DNA-dependent acetylation of p53 by the transcription coactivator p300. J Biol Chem 278: 13431-13441.
77. Yuan ZM, Huang Y, Ishiko T, Nakada S, Utsugisawa T, et al. (1999) Role for p300 in stabilization of p53 in the response to DNA damage. J Biol Chem 274: 1883-1886.
78. Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, et al. (2001) Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 8: 1243-1254.
79. Espinosa JM, Emerson BM, (2001) Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 8: 57-69.
80. Cazzalini O, Perucca P, Savio M, Necchi D, Bianchi L, et al. (2008) Interaction of p21(CDKN1A) with PCNA regulates the histone acetyltransferase activity of p300 in nucleotide excision repair. Nucleic Acids Res 36: 1713-1722.